Clinical trial
Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular…
NCT00312052 · Eisai Inc., Industry · Completed
Key facts
| NCT number | NCT00312052 |
|---|---|
| Title | Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Coronary Artery Disease |
| Official title | A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of E5555, and Its Effects on Markers of Intravascular Inflammation in Subjects With Coronary Artery Disease |
| Lead sponsor | Eisai Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Coronary Artery Disease |
| Intervention type | Drug |
| Interventions | E5555, Placebo |
| Enrollment | 720 |
| Start date | Sep 1, 2007 |
| Primary completion | Mar 1, 2008 |
| Completion | Aug 1, 2009 |
| First posted | Apr 7, 2006 |
| Last update posted | Dec 5, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: